Farxiga free 30 day trial
Before initiating FARXIGA, consider risk factors for ketoacidosis. If suspected, discontinue FARXIGA, evaluate and treat promptly.
![farxiga free 30 day trial farxiga free 30 day trial](https://ndclist.com/assets/spl/images/72ad22ae-efe6-4cd6-a302-98aaee423d69/farxiga-5mg-30s.jpg)
Assess patients who present with signs and symptoms of metabolic acidosis for ketoacidosis, regardless of blood glucose level.
![farxiga free 30 day trial farxiga free 30 day trial](https://slideplayer.com/slide/12174287/71/images/4/Observational+studies+Pragmatically+controlled.jpg)
Assess and correct volume status before initiating FARXIGA in patients with impaired renal function, elderly patients, or patients on loop diuretics.
#Farxiga free 30 day trial full
The full results will be submitted for presentation at a forthcoming medical meeting and AstraZeneca will now initiate discussions with global health authorities regarding early regulatory submissions. The primary endpoint of DAPA-CKD is a composite of worsening of renal function or death (defined as a composite endpoint of ≥50% sustained decline in estimated glomerular filtration rate (eGFR), onset of end stage renal disease (ESRD) or cardiovascular (CV) or renal death) in patients with CKD irrespective of the presence of type-2 diabetes (T2D). We are delighted with the Data Monitoring Committee recommendation and look forward to sharing the results with the medical community and patients with chronic kidney disease." Heerspink, University Medical Center Groningen, said: "It has been a privilege to be involved in this trial. David Wheeler, University College London, and Prof.
![farxiga free 30 day trial farxiga free 30 day trial](https://assets.medpagetoday.net/media/images/82xxx/82129.jpg)
#Farxiga free 30 day trial trial
The co-chairs of the trial and its Executive Committee Prof. FARXIGA has the potential to change the management of chronic kidney disease for patients around the world." We are very pleased the Data Monitoring Committee concluded that patients experienced overwhelming benefit. Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: "Chronic kidney disease patients have limited treatment options, particularly those without type-2 diabetes. The decision to stop the trial early was made following a routine assessment of efficacy and safety which showed FARXIGA's benefits earlier than originally anticipated and AstraZeneca will now initiate closure of the trial.